Format

Send to

Choose Destination
Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2581-2589. doi: 10.1007/s00259-019-04477-3. Epub 2019 Aug 13.

Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic 18F-FET PET.

Author information

1
Department of Nuclear Medicine, University Hospital, Ludwig Maximilians-University Munich, Munich, Germany.
2
German Cancer Consortium (DKTK), partner site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany.
3
Department of Neurosurgery, University Hospital, Ludwig Maximilians-University Munich, Munich, Germany.
4
Department of Neuroradiology, University Hospital, Ludwig Maximilians-University Munich, Munich, Germany.
5
Center for Neuropathology and Prion Research, Ludwig-Maximilians-University Munich, Munich, Germany.
6
Department of Nuclear Medicine, University Hospital, Ludwig Maximilians-University Munich, Munich, Germany. Nathalie.albert@med.uni-muenchen.de.
7
German Cancer Consortium (DKTK), partner site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany. Nathalie.albert@med.uni-muenchen.de.

Abstract

PURPOSE:

According to the updated WHO classification of gliomas with its emphasis on molecular parameters, tumours with an IDH-wildtype status have a dismal prognosis. To ensure timely adjustment of treatment, demand for non-invasive prediction methods is high. 18F-FET PET has been shown to be an important diagnostic tool for glioma management. The aim of this study was to assess the value of dynamic 18F-FET PET for the non-invasive prediction of the IDH-mutation status.

METHODS:

Newly diagnosed WHO grade II-IV glioma patients with MRI and dynamic 18F-FET PET were included. The 18F-FET PET parameters mean and maximal tumour-to-background ratio (TBRmean, TBRmax) and minimal time-to-peak (TTPmin) were evaluated. The diagnostic power for the prediction of the IDH genotype (positive/negative predictive value) was tested in the overall study group and in the subgroup of non-contrast enhancing gliomas.

RESULTS:

Three hundred forty-one patients were evaluated. Molecular analyses revealed 178 IDH-mutant and 163 IDH-wildtype tumours. Overall, 270/341 gliomas were classified as 18F-FET-positive (TBRmax > 1.6), 90.2% of the IDH-wildtype and 69.1% of IDH-mutant gliomas. Median TBRmax was significantly higher in IDH-wildtype compared with IDH-mutant gliomas (2.9 vs. 2.3, p < 0.001); however, ROC-analyses revealed no reliable cutoff due to a high overlap (range 1.0-7.1 vs. 1.1-7.9). Dynamic analysis revealed a significantly shorter TTPmin in IDH-wildtype gliomas; using TTPmin ≤ 12.5 min as indicator for IDH-wildtype gliomas, a positive predictive value of 87% was reached (negative predictive value 72%, AUC = 0.796, p ≤ 0.001). A total of 161/341 gliomas did not show contrast enhancement on MRI; even within this subgroup, TTPmin ≤ 12.5 min remained a good predictor of IDH-wildtype glioma (positive predictive value 83%, negative predictive value 90%; AUC = 0.868, p < 0.001).

CONCLUSION:

A short TTPmin in dynamic 18F-FET PET serves as good predictor of highly aggressive IDH-wildtype status in gliomas. In particular, a high diagnostic power was observed in the subgroup of non-contrast enhancing gliomas, which helps to identify patients with worse prognosis.

KEYWORDS:

18F-FET PET; Glioma; IDH mutation status; Non-invasive grading

PMID:
31410540
DOI:
10.1007/s00259-019-04477-3

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center